F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

DigestiveCare, Inc. is a medical group of board certified physicians specializing in gastrointestinal evaluations and treatment. The Endoscopy unit at DigestiveCare is accredited by The Ohio Department of Health, Medicare, AAAHC (Accreditation Association for Ambulatory Health Care) and has received the ASGE (American Society for Gastrointestinal Endoscopy) Certificate of Recognition of Quality in Endoscopy. DigestiveCare’s main office is located at 75 Sylvania Drive in Beavercreek, Ohio. They have three satellite offices in Vandalia, Miamisburg and Springboro.

Roche Palo Alto, engages in the discovery, development, and marketing of medicines for inflammatory or viral diseases. The company provides medicines for the treatment for a range of diseases, including severe asthma, chronic obstructive pulmonary disease, and rheumatoid arthritis. The company was formerly known as Syntex (U.S.A.) LLC and changed its name in 1994. The company was incorporated in 1960 and is based in Palo Alto, California. Roche Palo Alto, LLC operates as a subsidiary of Roche Holding AG. Source (businessweek) {http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=8102245}

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

Helmholtz-Zentrum für Infektionsforschung GmbH provides bio-medical research and development services. The firm engages in research projects focused on infection biology and its clinical application and practical implementation. It also specializes in the examination of pathogens that are either medically relevant or that can be used as models for the research of infections. Its research topics encompass bacterial and viral pathogens, immune response, and anti-infectives. The company was founded in 1965 and is headquartered in Braunschweig, Germany.

Pharmasset Inc is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Their primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus, or HBV, hepatitis C virus, or HCV and human immunodeficiency virus, or HIV. Their research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication. They are currently focusing on three product candidates, two of which they are developing themselves and one of which they are developing with a strategic partner: • Clevudine, for the treatment of HBV, expected to enter Phase 3 registration clinical trials in the second calendar quarter of 2007; • R7128, a pro-drug of PSI-6130 for the treatment of HCV, in a Phase 1 clinical trial; and • Racivir, for the treatment of HIV, in a Phase 2 clinical trial.

SBI Pharmaceuticals is a treatment foundation, and treatment methods vary greatly depending on whether or not the cancer has invaded the muscle layer. Non-muscle invasive bladder cancer accounts for approximately half of all cases. Bladder tumour resection (also known as bladder cancer endoscopic resection, TURBT) removes the cancer while leaving the bladder intact.

Part of Danone SA, Nutricia NV is a Dutch company located in Zoetermeer that manufactures dry, condensed and evaporated dairy products.

Ignyta is a scientifically-driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Their goal is to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide. Ignyta was incorporated in 2011 and operates in San Diego, California.

Part of Roche Holding AG, Hoffmann-La Roche Ltd. is a Canadian company located in Mississauga, ON, that manufactures pharmaceutical drugs.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Gilead Pharmasset LLC, part of Gilead Sciences, Inc., is a company headquartered in Princeton, NJ, that discovers, develops and commercializes therapeutic products and treatments for viral diseases.

Yamanouchi Pharmaceutical Co. Ltd. manufactures and markets drugs, quasi-drugs and medical devices. It used to promote collaboration with other pharmaceutical companies as well as bioventure companies and academia to raise the quality and speed of its R&D activities. It was founded in 1923. The company was headquartered in Tokyo, JP

Hadasit is the technology transfer company of Hadassah Medical Center in Jerusalem. They transform the cutting-edge research coming out of Hadassah into marketable medical technologies. They turn ground-breaking ideas into viable products and services that can change the world and better humanity. For more than a century, Hadassah has set the standard of excellence for medical care and research in Israel. Their doctors and scientists are on the frontlines, uniquely positioned to pinpoint ever-evolving medical needs. Their experience and ingenuity has yielded new ideas with huge potential in all areas of medicine, including therapeutics, diagnostic medical devices, and digital health. More than half of all hospital research in Israel is conducted at Hadassah. Hadasit is Hadassah’s vehicle for commercialization of the intellectual property and R&D capabilities developed there. Hadasit holds exclusive rights to every innovation and invention emerging from Hadassah and they are dedicated to bringing these life-saving technologies to the general public.

Hua Medicine (Shanghai) Co., Ltd. is a private company headquartered in Shanghai, China, that engages in drug development. The firm was founded in 2011 by Li Chen, who has been the CEO since then.

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, they are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.

Guangzhou Yunzhong Biotechnology Co., Ltd., established on 2011-10-20, Business scope includes biotechnology development services;Biotechnology Consulting,communication service;